Takeshi Yamasaki

Dr. Takeshi Yamasaki


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Cancer Letters
Verified
Journal Article
Open access
YTYuji Takeyama
Yuji Takeyama
MKMinoru Kato
Minoru Kato
STSatoshi Tamada
Satoshi Tamada
YAYukari Azuma
Yukari Azuma
YSYasuomi Shmizu
Yasuomi Shmizu
TNTatsuya Nakatani
Tatsuya Nakatani
Myeloid-derived suppressor cells (MDSCs) are one of the key players that contribute to immune evasion. The purpose of the present study was to investigate whether MDSCs could be a novel target for the treatment of cisplatin-resistant bladder cancer. We established cisplatin-resistant bladder cancer cell lines (MB49R, MBT-2R, and T24R) and evaluated chemokine expression and MDSC expansion. We also assessed the antitumor effect by depleting MDSCs with or without a α-PD-L1 antibody using MB49R xenograft models. The chemokine expression of CXCL1, CXCL2, and CCL2 increased in cisplatin-resistant cells compared to those in their parent strains. Monocytic MDSCs (Mo-MDSCs) were observed more frequently compared to polymorphonuclear MDSCs (PMN-MDSCs) in MB49R tumors. The immunosuppressive genes arginase 1 and iNOS were comparably expressed in each MDSC subtype. In vivo, combination therapy targeting both PMN- and Mo-MDSCs using α-Gr1 and α-Ly6C antibodies significantly reduced tumor volume with increased infiltration of CD8 T cells in the tumor. Finally, co-targeting pan-MDSCs and PD-L1 remarkably reduced the tumor growth. These findings suggest that targeting MDSCs might enhance the therapeutic effect of immune checkpoint inhibitors in cisplatin-resistant bladder cancers.

11 April 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TITaro Iguchi
Taro Iguchi
STSatoshi Tamada
Satoshi Tamada
MKMinoru Kato
Minoru Kato
SYSayaka Yasuda
Sayaka Yasuda
TYTakeshi Yamasaki
Takeshi Yamasaki
TNTatsuya Nakatani
Tatsuya Nakatani
Enzalutamide is an oral androgen receptor targeted agent that has been shown to improve survival in PREVAIL trials and has been approved for patients with chemo-naïve metastatic castration-resistant prostate cancer (CRPC). Meanwhile, flutamide is a non-steroidal oral anti-androgen that was commonly used before the approval of bicalutamide. The objective of the OCUU-CRPC study is to compare the efficacy and safety between second-line hormonal therapy of enzalutamide and flutamide as alternative anti-androgen therapy (AAT) after combined androgen blockade (CAB) therapy that included bicalutamide in patients with CRPC. A total of 100 patients with CRPC with or without distant metastases after disease progression who received CAB therapy with bicalutamide were randomly assigned at a 1:1 ratio according to distant metastases to the enzalutamide (160 mg/day, 4 × 40 mg capsules once daily) and flutamide (375 mg/day; 3 × 125 mg tablets thrice daily) groups. The primary endpoint for the drug efficacy is the response rate of prostate-specific antigen (PSA) (i.e., the ratio of patients whose PSA declined by ≥50% from baseline) at 3 months. Meanwhile, the secondary endpoints are PSA progression rate at 3 and 6 months, PSA response rate at 6 months, change in quality of life, PSA progression-free survival, and safety. The patient registration started in January 2015 and will end in March 2018, and the follow-up period is 6 months after the last patient registration. The main result will be reported in March 2019. In the OCUU-CRPC study, we compare the efficacy and safety of enzalutamide or alternative AAT with flutamide in participants with CRPC who were previously treated with a CAB therapy with bicalutamide. The expected results of this study will be that enzalutamide is superior to flutamide in terms of PSA response. A longer time to disease progression with enzalutamide over flutamide may translate to better overall survival. However, flutamide may be more accessible for patients owing to its lower cost than enzalutamide. The OCUU-CRPC study was prospectively registered at clinicaltrials.gov ( NCT02346578 , January 2015) and University Hospital Medical Information Network ( UMIN000016301 , January 2015).

18 July 2018 in Basic and Clinical Andrology
Verified
Journal Article
Open access
PDF file
JAJumpei Asakawa
Jumpei Asakawa
TITaro Iguchi
Taro Iguchi
STSatoshi Tamada
Satoshi Tamada
SYSayaka Yasuda
Sayaka Yasuda
NNNoriko Ninomiya
Noriko Ninomiya
TNTatsuya Nakatani
Tatsuya Nakatani
The aim of our retrospective study was to evaluate the 5-year survival and time to castration resistant prostate cancer in patients with hormone sensitive prostate cancer treated with the gonadotropin releasing hormone antagonist, degarelix. Another aim was to evaluate the effects of changing the treatment from degarelix to a gonadotropin releasing hormone agonist after achieving stable disease control, on the clinical and oncological outcomes. Our analysis was based on the data of 108 patients with prostate cancer who were treated with degarelix. Of these, the treatment was changed from degarelix to a gonadotropin releasing hormone agonist in 57 patients (changed group), and the treatment with degarelix was continued in the other 51 (continued group). The overall 5-year survival was statistically superior in the changed (96.6%) group than that in the continued (74.1%) group (p = 0.006). The 5-year cancer-specific survival was also superior in the changed (100%) group than that in the continued (84.6%) group (p = 0.027). The average time to castration resistant prostate cancer was comparable in both the changed (43.3 months) and continued (35.2 months) groups (p = 0.117). Lower serum levels of prostate specific antigen and alkaline phosphatase were maintained after changing the therapy from degarelix to a gonadotropin releasing hormone agonist. Degarelix is effective in the treatment of prostate cancer. Degarelix therapy can also be safely changed to a gonadotropin releasing hormone agonist without any adverse clinical or oncological effects.

24 June 2025 in International Journal of Urology
Verified
Journal Article
Open access
KHKosuke Hamada
Kosuke Hamada
TYTakeshi Yamasaki
Takeshi Yamasaki
SYShoma Yamamoto
Shoma Yamamoto
TMTaisuke Matsue
Taisuke Matsue
NYNao Yukimatsu
Nao Yukimatsu
Junji UchidaJunji Uchida
Junji Uchida
Objectives: Non‐renorrhaphy technique during partial nephrectomy has not been sufficiently studied. This study aimed to evaluate the surgical outcomes of the non‐renorrhaphy technique in robot‐assisted partial nephrectomy (RAPN) for tumors with RENAL scores of 10–12. Methods: We retrospectively analyzed 51 consecutive patients who underwent RAPN with or without renorrhaphy for RENAL score 10–12 tumors at Osaka Metropolitan University Hospital between March 2015 and December 2023. Perioperative outcomes were compared between 16 patients in the nonrenorrhaphy group and 35 patients in the renorrhaphy group. Univariate and multivariate linear regression analyses were conducted to identify predictors of renal function and renal parenchymal volume preservation. Results: Patient demographics and preoperative tumor characteristics exhibited no significant differences between the two groups. Operative time was significantly shorter in the nonrenorrhaphy group (185 vs. 217 min, p = 0.0016). The preservation rate of renal parenchymal volume was significantly higher in the nonrenorrhaphy group (86.7 vs. 74.2%, p = 0.0016), but there was no significant difference in the preservation rate of estimated glomerular filtration rate ( p = 0.6380). No significant difference was observed in the incidence of major complications (Clavien‐Dindo grade ≥ 3) between the two groups. Urinary leakage occurred in both groups ( p = 0.9399). In univariate and multivariate analyses, renorrhaphy and clinical tumor size were identified as significant predictors of renal parenchymal volume preservation. Conclusions: Even in cases with RENAL scores of 10–12, the non‐renorrhaphy technique appears to be a feasible and safe approach, and may be associated with better preservation of renal parenchymal volume.

4 April 2024 in IJU Case Reports
Verified
Journal Article
Open access
NYNao Yukimatsu
Nao Yukimatsu
TYTakeshi Yamasaki
Takeshi Yamasaki
KIKeiko Iguchi
Keiko Iguchi
TOTaiyo Otoshi
Taiyo Otoshi
MKMinoru Kato
Minoru Kato
JUJunji Uchida
Junji Uchida
Introduction: Urinary fistula is a rare complication following robot‐assisted partial nephrectomy. For cases refractory to conservative treatment, only ureteral stent placement and percutaneous drainage are the established treatment alternatives.Case presentation: A 44‐year‐old man presented with urinary fistula 3 weeks after robot‐assisted partial nephrectomy for right renal cell carcinoma. Follow‐up observations were conducted for 2 weeks; however, no improvements were observed. Additionally, the patient did not improve following percutaneous drainage and ureteral stent insertion. Subsequently, the patient received percutaneous injections of fibrin glue, with the urinary fistula showing significant improvements on the following day.Conclusion: Our findings indicated that percutaneous fibrin glue injection can effectively treat refractory urinary fistula following partial nephrectomy.

17 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Junji UchidaJunji Uchida
Junji Uchida
SNShunji Nishide
Shunji Nishide
YTYuji Takeyama
Yuji Takeyama
TOTaiyo Otoshi
Taiyo Otoshi
MKMinoru Kato
Minoru Kato
KKKatsuyuki Kuratsukuri
Katsuyuki Kuratsukuri
Background/Objectives: Letermovir is effective for cytomegalovirus (CMV) prophylaxis after kidney transplantation, but cytochrome P450 3A inhibition may alter tacrolimus and everolimus exposure. We evaluated changes in trough concentrations and dose requirements during letermovir initiation and discontinuation in de novo kidney transplant recipients. Methods: This single-center retrospective observational study included 20 living-donor kidney transplant recipients with D+/R− or R+ CMV serostatus receiving everolimus-based reduced-tacrolimus immunosuppression and letermovir prophylaxis. Trough concentrations, daily doses, kidney allograft function, CMV out-comes, and safety were assessed descriptively. Results: After letermovir initiation, mean tacrolimus trough concentrations increased by approximately 40–60% and evero-limus trough concentrations by approximately 35–50%, requiring dose reductions of approximately 45% and 30–40%, respectively. By day 7 after discontinuation, mean tacrolimus and everolimus trough concentrations decreased to 57.4% and 65.9% of baseline, respectively, while daily doses increased to 136.6% and 132.5%, respectively. Group mean serum creatinine and eGFR remained within approximately 10% of base-line. No CMV DNAemia or disease, leukopenia, neutropenia, acute T cell-mediated re-jection, or antibody-mediated rejection occurred; gastrointestinal symptoms occurred in three recipients. Conclusions: Letermovir was associated with rapid, reversible changes in tacrolimus and everolimus trough concentrations and dose requirements. Intensive therapeutic drug monitoring is warranted at both initiation and discontinuation.